<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847090</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-177-302</org_study_id>
    <secondary_id>2018-000921-29</secondary_id>
    <nct_id>NCT03847090</nct_id>
  </id_info>
  <brief_title>Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria</brief_title>
  <acronym>URIROX-2</acronym>
  <official_title>Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, durability and long-term safety of
      reloxaliase in patients with enteric hyperoxaluria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study.
      This study is designed to determine the short- and long-term efficacy of reloxaliase in terms
      of reducing urinary oxalate excretion and clinical benefits compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 1-4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Efficacy will be assessed based on percent change from baseline to the average across Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with kidney stone disease progression (composite of symptomatic kidney stone(s) or finding of new or enlarged kidney stone(s) on imaging)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Efficacy will be assessed by comparing kidney stone disease progression rate on reloxaliase vs. placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 20% reduction from baseline in 24-hour urinary oxalate excretion during Weeks 1-4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Efficacy will be assessed based on proportion of subjects with ≥ 20% reduction from baseline to the average across Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 16-24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Efficacy will be assessed based on percent change from baseline to the average across Weeks 16-24, derived from all 24-hour collections during Weeks 16-24 on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations or emergency room (ER) visits or procedures for the management of kidney stones</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Efficacy will be assessed by comparing utilization on reloxaliase vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (eGFR) from baseline</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Efficacy will be assessed by comparing the rate of change in eGFR on reloxaliase vs. placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Enteric Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Reloxaliase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reloxaliase (ALLN-177) 142 mg of oxalate decarboxylase (equivalent to 3,750 units of enzyme activity) per capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reloxaliase</intervention_name>
    <description>Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day</description>
    <arm_group_label>Reloxaliase</arm_group_label>
    <other_name>ALLN-177</other_name>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Placebo capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provided informed consent

          2. Age 18 years or older

          3. Has an underlying enteric disorder associated with malabsorption with known or
             suspected history of hyperoxaluria (e.g., history of kidney stones or oxalate
             nephropathy)

          4. Urinary oxalate ≥ 50 mg/24 hr

          5. Has at least 1 documented kidney stone within 2 years

        Exclusion Criteria:

          1. Acute renal failure or estimated glomerular filtration rate (eGFR) &lt; 30 mL/minute/1.73
             m2

          2. Has a known genetic, congenital, or other cause of kidney stones

          3. Unable or unwilling to discontinue Vitamin C supplementation

          4. Cannot establish baseline kidney stone burden
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Kausz, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allena Pharmaceuticals, Inc</last_name>
    <phone>617-467-4577</phone>
    <phone_ext>398</phone_ext>
    <email>clinical302@allenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urological Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) Health System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IU Health Physicians</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University (IU) Nephrology</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Urology</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Urology Center, P.C./ GU Research Network</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Long Island Gastrointestinal Research Group</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Centers of NY</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina (UNC) - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati (UC) - Department of Nephrologyv</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Nephrology Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Division of Nephrology</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Silverado Research Inc</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T2C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV) Lausanne Nephrology Department</name>
      <address>
        <city>Lausanne</city>
        <zip>CH 1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/27529510</url>
    <description>A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30783888</url>
    <description>ALLN-177, oral enzyme therapy for hyperoxaluria</description>
  </link>
  <reference>
    <citation>Langman CB, Grujic D, Pease RM, Easter L, Nezzer J, Margolin A, Brettman L. A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme. Am J Nephrol. 2016;44(2):150-8. doi: 10.1159/000448766. Epub 2016 Aug 17.</citation>
    <PMID>27529510</PMID>
  </reference>
  <reference>
    <citation>Lingeman JE, Pareek G, Easter L, Pease R, Grujic D, Brettman L, Langman CB. ALLN-177, oral enzyme therapy for hyperoxaluria. Int Urol Nephrol. 2019 Apr;51(4):601-608. doi: 10.1007/s11255-019-02098-1. Epub 2019 Feb 19.</citation>
    <PMID>30783888</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney stone</keyword>
  <keyword>hyperoxaluria</keyword>
  <keyword>enteric hyperoxaluria</keyword>
  <keyword>oxalate</keyword>
  <keyword>kidney calcification</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

